PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
Fredriksson
Anna
A
Karolinska Pharmacy, Karolinska Hospital, Stockholm, Sweden.
Stone-Elander
Sharon
S
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D004341:Drug Evaluation / Q000379:methods*; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000882:Haplorhini; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007553:Isotope Labeling / Q000379:methods; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011799:Quinazolines / Q000494:pharmacology; D019275:Radiopharmaceuticals; D051381:Rats; D014055:Tomography, Emission-Computed / Q000662:veterinary; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D011799:Quinazolines; D019275:Radiopharmaceuticals; D066246:ErbB Receptors; C088860:4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline